Total Payments
$244,103
2024 Payments
$14,278
Companies
21
Transactions
208
Medicare Patients
31
Medicare Billing
$2,773
Payment Breakdown by Category
Consulting$133,558 (54.7%)
Travel$58,442 (23.9%)
Other$39,612 (16.2%)
Research$7,011 (2.9%)
Food & Beverage$5,480 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $133,558 | 52 | 54.7% |
| Travel and Lodging | $58,442 | 51 | 23.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,612 | 12 | 16.2% |
| Unspecified | $7,011 | 12 | 2.9% |
| Food and Beverage | $5,480 | 81 | 2.2% |
Payments by Type
General
$237,092
196 transactions
Research
$7,011
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $54,828 | 33 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $50,745 | 62 | $0 (2024) |
| GlaxoSmithKline, LLC. | $35,705 | 33 | $0 (2022) |
| Boehringer Ingelheim Taiwan Ltd. | $23,181 | 4 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,466 | 4 | $0 (2022) |
| AstraZeneca AB | $14,459 | 8 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $7,857 | 10 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,279 | 5 | $0 (2023) |
| Mylan Specialty L.P. | $6,390 | 10 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $4,838 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,278 | 10 | Regeneron Healthcare Solutions, Inc. ($7,437) |
| 2023 | $19,498 | 30 | AstraZeneca Pharmaceuticals LP ($9,031) |
| 2022 | $11,329 | 9 | GlaxoSmithKline, LLC. ($7,511) |
| 2021 | $15,923 | 5 | AstraZeneca UK Limited ($10,500) |
| 2020 | $29,801 | 18 | AstraZeneca AB ($10,459) |
| 2019 | $56,580 | 33 | Boehringer Ingelheim Taiwan Ltd. ($22,243) |
| 2018 | $32,179 | 37 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,752) |
| 2017 | $64,516 | 66 | AstraZeneca Pharmaceuticals LP ($20,673) |
All Payment Transactions
208 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,879.00 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $584.50 | General |
| 10/07/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $62.85 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/07/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.07 | General |
| 07/30/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,923.00 | General |
| Category: Immunology | ||||||
| 01/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $4,753.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,358.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $679.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 11/21/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 10/11/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $105.48 | General |
| Category: Respiratory | ||||||
| 09/05/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $7,249.50 | General |
| 08/31/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $119.81 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/31/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $76.19 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/31/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $42.86 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/31/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $42.86 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,876.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,584.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $646.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/08/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Respiratory | ||||||
| 08/04/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 07/22/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $78.79 | General |
| Category: Respiratory | ||||||
| 07/22/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $259.50 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 34 STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND EFFECTS ON THE ALPHA1-PROTEINASE INHIBITOR A1PI LEVELS IN EPITHELIAL LINING FLUID FOLLOWING GLASSIA THERAPY IN A1PI-DEFICIENT SUBJECTS | Shire North American Group Inc | $3,553 | 3 |
| A PHASE 3/4 STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND EFFECTS ON THE ALPHA1-PROTEINASE INHIBITOR (A1PI) LEVELS IN EPITHELIAL LINING FLUID FOLLOWING GLASSIA THERAPY IN A1PI-DEFICIENT SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $2,450 | 3 |
| A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | GlaxoSmithKline, LLC. | $983.44 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 16 | $3,304 | $1,855 |
| 2020 | 1 | 18 | 20 | $3,000 | $917.35 |
Total Patients
31
Total Services
36
Medicare Billing
$2,773
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 13 | 16 | $3,304 | $1,855 | 56.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 20 | $3,000 | $917.35 | 30.6% |
About Dr. Barry Make, MD
Dr. Barry Make, MD is a Pulmonary Disease healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801976303.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Make, MD has received a total of $244,103 in payments from pharmaceutical and medical device companies, with $14,278 received in 2024. These payments were reported across 208 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($133,558).
As a Medicare-enrolled provider, Make has provided services to 31 Medicare beneficiaries, totaling 36 services with total Medicare billing of $2,773. Data is available for 2 years (2020–2023), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Denver, CO
- Active Since 10/17/2006
- Last Updated 02/26/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1801976303
Products in Payments
- STIOLTO (Drug) $22,243
- DUPIXENT (Biological) $19,354
- SYMBICORT (Drug) $13,192
- STIOLTO RESPIMAT (Drug) $9,752
- BEVESPI AEROSPHERE (Drug) $9,725
- TRELEGY ELLIPTA (Drug) $7,600
- Yupelri (Drug) $6,390
- NUCALA (Biological) $6,175
- GLASSIA (Biological) $6,003
- FASENRA (Drug) $5,514
- BROVANA (Drug) $4,773
- BREZTRI AEROSPHERE (Drug) $4,668
- SPIRIVA (Drug) $4,589
- TUDORZA PRESSAIR (Drug) $3,752
- Other Resp ServSales (Device) $3,526
- BREZTRI (Drug) $2,663
- Spiration Valve System (Device) $2,295
- AIRSUPRA (Drug) $1,630
- Wellcentive Undiv (Device) $458.60
- Xolair (Biological) $192.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Denver
Dr. Ronald Balkissoon, Md, MD
Pulmonary Disease — Payments: $1.5M
Pulmonary Disease $1.5M
Kevin Brown, Md, MD
Pulmonary Disease — Payments: $333,953
Pulmonary Disease $333,953
David Griffith, Md, MD
Pulmonary Disease — Payments: $287,061
Pulmonary Disease $287,061
Dr. David Beuther, Md, MD
Pulmonary Disease — Payments: $155,207
Pulmonary Disease $155,207
Evans Fernandezperez, M.d, M.D
Pulmonary Disease — Payments: $149,782
Pulmonary Disease $149,782
Dr. Robert Sandhaus, M.d., Ph.d, M.D., PH.D
Pulmonary Disease — Payments: $106,680
Pulmonary Disease $106,680